Mutic S, Dempsey JF (2014) The viewRay system: magnetic resonance-guided and controlled radiotherapy. Semin Radiat Oncol 24:196–199
Raaymakers BW, Lagendijk JJ, Overweg J, Kok JG, Raaijmakers AJ, Kerkhof EM et al (2009) Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept. Phys Med Biol 54:N229–N237
Article PubMed CAS Google Scholar
Teunissen FR, Willigenburg T, Tree AC, Hall WA, Choi SL, Choudhury A et al (2023) Magnetic resonance-guided adaptive radiation therapy for prostate cancer: the first results from the MOMENTUM study—an international registry for the evidence-based introduction of magnetic resonance-guided adaptive radiation therapy. Pract Radiat Oncol 13:e261–e269
Christiansen RL, Dysager L, Hansen CR, Jensen HR, Schytte T, Nyborg CJ et al (2022) Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment. Radiother Oncol 167:165–171
Article PubMed CAS Google Scholar
Kishan AU, Ma TM, Lamb JM, Casado M, Wilhalme H, Low DA et al (2023) Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial. JAMA Oncol 9:365–373
Article PubMed PubMed Central Google Scholar
Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M et al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5‑year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet Oncol 394:385–395
Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W et al (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20:1531–1543
Article PubMed PubMed Central Google Scholar
Draulans C, Van Der HUA, Haustermans K, Pos FJ, van der Voort van Zyp J, De Boer H et al (2020) Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol 147:92–98
Kerkmeijer LG, Groen VH, Pos FJ, Haustermans K, Monnikhof EM, Smeenk RJ et al (2021) Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results of the FLAME randomized phase III trial. J Clin Oncol 39:787–796
Article PubMed CAS Google Scholar
Pang EPP, Knight K, Fan Q, Tan SXF, Ang KW, Master Z et al (2018) Analysis of intra-fraction prostate motion and derivation of duration-dependent margins for radiotherapy using real-time 4D ultrasound. Phys Imaging Radiat Oncol 5:102–107
Article PubMed PubMed Central Google Scholar
Ballhausen H, Li M, Hegemann NS, Ganswindt U, Belka C (2015) Intra-fraction motion of the prostate is a random walk. Phys Med Biol 60:549–563
Article PubMed CAS Google Scholar
Kotte Antj, Hofman P, Lagendijk JJW, van Vulpen M, van der Heide UA (2007) Intrafraction motion of the prostate during external-beam radiation therapy: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 69:419–425
Jmour O, Benna M, Champagnol P, Mrad BM, Hamrouni A, Obeid L et al (2020) CBCT evaluation of inter- and intra-fraction motions during prostate stereotactic body radiotherapy: a technical note. Radiat Oncol 15:85
Article PubMed PubMed Central Google Scholar
McPartlin AJ, Li XA, Kershaw LE, Heide U, Kerkmeijer L, Lawton C et al (2016) MR-linac consortium MRI-guided prostate adaptive radiotherapy—a systematic review. Radiother Oncol 119:371–380
Article PubMed CAS Google Scholar
Tetar SU, Bruynzeel AME, Lagerwaard FJ, Slotman BJ, Bohoudi O, Palacios MA (2019) Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer. Phys Imaging Radiat Oncol 9:69–76
Article PubMed PubMed Central Google Scholar
Keizer DDM, Kerkmeijer LGW, Willigenburg T, Den Hartogh MD, Van Der Voort van Zyp JR, De Groot-van Breugel EN et al (2020) Prostate intrafraction motion during the full course of MR-guided radiotherapy sessions. Radiother Oncol 151:88–94
De Muinck Keizer DM, Willigenburg T, Van Der Voort van Zyp JR, Raaymakers BW, Lagendijk JJW, de Boer JCJ (2021) Seminal vesicle intrafraction motion during the delivery of radiotherapy sessions on a 1.5 T MR-Linac. Radiother Oncol 162:162–169
de Muinck Keizer D, Kerkmeijer L, Willigenburg T, van Lier A, den Hartogh M, Van Zyp JVDV et al (2020) Prostate intrafraction motion during the preparation and delivery of MR-guided radiotherapy sessions on a 1.5 T MR-Linac. Radiat Oncol 151:88–94
de Muinck Keizer DM, van der Voort van Zyp JRN, de Groot-van Breugel EN, Raaymakers BW, Lagendijk JJW et al (2021) On-line daily plan optimization combined with a virtual couch shift procedure to address intrafraction motion in prostate magnetic resonance guided radiotherapy. Phys Imaging Radiat Oncol 19:90–95
Article PubMed PubMed Central Google Scholar
Menten MJ, Mohajer JK, Nilawar R, Bertholet J, Dunlop A, Pathmanathan AU et al (2020) Automatic reconstruction of the delivered dose of the day using MR-linac treatment log files and online MR imaging. Radiother Oncol 145:88–94
Article PubMed PubMed Central Google Scholar
Kontaxis C, de Muinck Keizer DM, Kerkmeijer LGW, Willigenburg T, den Hartogh MD, van der Voort van Zyp JRN et al (2021) Delivered dose quantification in prostate radiotherapy using online 3D cine imaging and treatment log files on a combined 1.5T magnetic resonance imaging and linear accelerator system. Phys Imaging Radiat Oncol 15:23–29
Xiong Y, Rabe M, Nierer L, Kawula M, Corradini S, Belka C et al (2023) Assessment of intrafractional prostate motion and its dosimetric impact in MRI-guided online adaptive radiotherapy with gating. Strahlenther Onkol 199(6):544–553
van Herk M, Remeijer P, Rasch C, Lebesque JV (2000) The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys 47:1121–1135
van der Bijl E, Remeijer P, Sonke JJ, van der Heide UA, Janssen TM (2022) Adaptive margins for online adaptive radiotherapy. Phys Med Biol 67:195016
Janssen TM, van der Heide UA, Remeijer P, Sonke JJ, van der Bijl E (2022) A margin recipe for the management of intra-fraction target motion in radiotherapy. Phys Imaging Radiat Oncol 14:159–166
Dassen MG, Janssen T, Kusters M, Pos F, Kerkmeijer LGW, van der Heide UA et al (2023) Comparing adaptation strategies in MRI-guided online adaptive radiotherapy for prostate cancer: Implications for treatment margins. Radiother Oncol 186:109761
Article PubMed CAS Google Scholar
Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM et al (2019) Adaptive radiotherapy: the elekta unity MR-linac concept. Clin Transl Radiat Oncol 18:54–59
PubMed PubMed Central Google Scholar
de Mol van Otterloo SR, Christodouleas JP, Blezer ELA, Akhiat H, Brown K, Choudhury A, Eggert D et al (2020) The MOMENTUM study: an international registry for the evidence-based introduction of MR-guided adaptive therapy. Front Oncol 10:1328
Article PubMed PubMed Central Google Scholar
Van Herk M (2004) Errors and margins in radiotherapy. Semin Radiat Oncol 14:52–64
Ballhausen H, Reiner M, Kantz S, Belka C, Sohn M (2013) The random walk model of intrafraction movement. Phys Med Biol 58:2413–2427
Article PubMed CAS Google Scholar
Ghadjar P, Fiorino C, Munck Af Rosenschöld P, Pinkawa M, Zilli T, van der Heide UA (2019) ESTRO ACROP consensus guideline on the use of image guided radiation therapy for localized prostate cancer. Radiother Oncol 141:49–61
Comments (0)